Boston, MA, United States of America

Angie R Angeles

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 11.2

ph-index = 1


Company Filing History:


Years Active: 2014-2016

Loading Chart...
Loading Chart...
3 patents (USPTO):

Title: Innovations by Angie R Angeles

Introduction

Angie R Angeles is a prominent inventor based in Boston, MA (US). She has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target cancer treatment. With a total of three patents to her name, her work is recognized for its potential impact on medical science.

Latest Patents

One of her latest patents involves compounds that are ERK inhibitors. These compounds, characterized by a pyrazolopyridine base structure, are designed to treat cancer effectively. The patent discloses methods of using these compounds in therapeutic applications. Another notable patent focuses on Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors. This invention provides a formula for these compounds, which are useful in treating cancer and other disorders related to mTOR deregulation.

Career Highlights

Angie R Angeles is currently associated with Merck Sharp & Dohme Corporation, where she continues to innovate in the pharmaceutical sector. Her work is instrumental in advancing cancer treatment methodologies, showcasing her dedication to improving patient outcomes.

Collaborations

Throughout her career, Angie has collaborated with notable colleagues, including Umar Faruk Mansoor and Matthew H Daniels. These partnerships have fostered a collaborative environment that enhances the research and development of new therapeutic solutions.

Conclusion

Angie R Angeles stands out as a key figure in the field of pharmaceutical innovation. Her patents reflect her commitment to addressing critical health challenges, particularly in cancer treatment. Her contributions are paving the way for future advancements in medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…